Copyright Reports & Markets. All rights reserved.

Global Deutenzalutamide Soft Capsules Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Deutenzalutamide Soft Capsules Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 28 Capsules Per Box
    • 1.3.3 112 Capsules Per Bottle
  • 1.4 Market Analysis by Combined medication
    • 1.4.1 Overview: Global Deutenzalutamide Soft Capsules Consumption Value by Combined medication: 2021 Versus 2025 Versus 2032
    • 1.4.2 Deuteroenzalutamide in combination with Androgen Synthesis Inhibitors
    • 1.4.3 Deuteroenzalutamide in combination with Hormonal Antineoplastic Drugs
  • 1.5 Market Analysis by Production Technology
    • 1.5.1 Overview: Global Deutenzalutamide Soft Capsules Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.5.2 Innovator
    • 1.5.3 Generic
  • 1.6 Market Analysis by Sales Channels
    • 1.6.1 Overview: Global Deutenzalutamide Soft Capsules Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospital
    • 1.6.3 Retail
    • 1.6.4 Online
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Deutenzalutamide Soft Capsules Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Metastatic Castration-Resistant Prostate Cancer
    • 1.7.3 Non-Metastatic Castration-Resistant Prostate Cancer
    • 1.7.4 Metastatic Hormone-Sensitive Prostate Cancer
    • 1.7.5 Others
  • 1.8 Global Deutenzalutamide Soft Capsules Market Size & Forecast
    • 1.8.1 Global Deutenzalutamide Soft Capsules Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Deutenzalutamide Soft Capsules Sales Quantity (2021-2032)
    • 1.8.3 Global Deutenzalutamide Soft Capsules Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Hinovapharma
    • 2.1.1 Hinovapharma Details
    • 2.1.2 Hinovapharma Major Business
    • 2.1.3 Hinovapharma Deutenzalutamide Soft Capsules Product and Services
    • 2.1.4 Hinovapharma Deutenzalutamide Soft Capsules Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Hinovapharma Recent Developments/Updates

3 Competitive Environment: Deutenzalutamide Soft Capsules by Manufacturer

  • 3.1 Global Deutenzalutamide Soft Capsules Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Deutenzalutamide Soft Capsules Revenue by Manufacturer (2021-2026)
  • 3.3 Global Deutenzalutamide Soft Capsules Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Deutenzalutamide Soft Capsules by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Deutenzalutamide Soft Capsules Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Deutenzalutamide Soft Capsules Manufacturer Market Share in 2025
  • 3.5 Deutenzalutamide Soft Capsules Market: Overall Company Footprint Analysis
    • 3.5.1 Deutenzalutamide Soft Capsules Market: Region Footprint
    • 3.5.2 Deutenzalutamide Soft Capsules Market: Company Product Type Footprint
    • 3.5.3 Deutenzalutamide Soft Capsules Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Deutenzalutamide Soft Capsules Market Size by Region
    • 4.1.1 Global Deutenzalutamide Soft Capsules Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Deutenzalutamide Soft Capsules Consumption Value by Region (2021-2032)
    • 4.1.3 Global Deutenzalutamide Soft Capsules Average Price by Region (2021-2032)
  • 4.2 North America Deutenzalutamide Soft Capsules Consumption Value (2021-2032)
  • 4.3 Europe Deutenzalutamide Soft Capsules Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Deutenzalutamide Soft Capsules Consumption Value (2021-2032)
  • 4.5 South America Deutenzalutamide Soft Capsules Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Deutenzalutamide Soft Capsules Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Deutenzalutamide Soft Capsules Sales Quantity by Type (2021-2032)
  • 5.2 Global Deutenzalutamide Soft Capsules Consumption Value by Type (2021-2032)
  • 5.3 Global Deutenzalutamide Soft Capsules Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Deutenzalutamide Soft Capsules Sales Quantity by Application (2021-2032)
  • 6.2 Global Deutenzalutamide Soft Capsules Consumption Value by Application (2021-2032)
  • 6.3 Global Deutenzalutamide Soft Capsules Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Deutenzalutamide Soft Capsules Sales Quantity by Type (2021-2032)
  • 7.2 North America Deutenzalutamide Soft Capsules Sales Quantity by Application (2021-2032)
  • 7.3 North America Deutenzalutamide Soft Capsules Market Size by Country
    • 7.3.1 North America Deutenzalutamide Soft Capsules Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Deutenzalutamide Soft Capsules Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Deutenzalutamide Soft Capsules Sales Quantity by Type (2021-2032)
  • 8.2 Europe Deutenzalutamide Soft Capsules Sales Quantity by Application (2021-2032)
  • 8.3 Europe Deutenzalutamide Soft Capsules Market Size by Country
    • 8.3.1 Europe Deutenzalutamide Soft Capsules Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Deutenzalutamide Soft Capsules Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Deutenzalutamide Soft Capsules Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Deutenzalutamide Soft Capsules Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Deutenzalutamide Soft Capsules Market Size by Region
    • 9.3.1 Asia-Pacific Deutenzalutamide Soft Capsules Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Deutenzalutamide Soft Capsules Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Deutenzalutamide Soft Capsules Sales Quantity by Type (2021-2032)
  • 10.2 South America Deutenzalutamide Soft Capsules Sales Quantity by Application (2021-2032)
  • 10.3 South America Deutenzalutamide Soft Capsules Market Size by Country
    • 10.3.1 South America Deutenzalutamide Soft Capsules Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Deutenzalutamide Soft Capsules Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Deutenzalutamide Soft Capsules Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Deutenzalutamide Soft Capsules Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Deutenzalutamide Soft Capsules Market Size by Country
    • 11.3.1 Middle East & Africa Deutenzalutamide Soft Capsules Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Deutenzalutamide Soft Capsules Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Deutenzalutamide Soft Capsules Market Drivers
  • 12.2 Deutenzalutamide Soft Capsules Market Restraints
  • 12.3 Deutenzalutamide Soft Capsules Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Deutenzalutamide Soft Capsules and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Deutenzalutamide Soft Capsules
  • 13.3 Deutenzalutamide Soft Capsules Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Deutenzalutamide Soft Capsules Typical Distributors
  • 14.3 Deutenzalutamide Soft Capsules Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Deutenzalutamide Soft Capsules market size was valued at US$ 30.87 million in 2025 and is forecast to a readjusted size of US$ 375 million by 2032 with a CAGR of 12.5% during review period.
    Deutenzalutamide soft capsules are a novel oral androgen receptor inhibitor modified by deuteration. By specifically binding to the androgen receptor and blocking its signal transduction, they inhibit the proliferation and survival of tumor cells, and are mainly used for the treatment of metastatic castration‑resistant prostate cancer. As a deuterated improved drug based on enzalutamide, its structural optimization enhances metabolic stability, prolongs its duration of action in vivo and improves safety. Featuring favorable oral absorption and convenient administration, it provides a better‑tolerated therapeutic option for patients with advanced prostate cancer and holds important clinical value in the field of genitourinary oncology.In 2025, global Deutenzalutamide soft capsules production reached approximately 120,000 units.
    Deutenzalutamide soft capsules, as the first deuterated androgen receptor inhibitor approved in China, have filled the gap in domestic innovative drugs for the targeted treatment of metastatic castration‑resistant prostate cancer. Relying on deuteration technology, they have achieved remarkable improvements in metabolic stability and safety, showing clear clinical advantages in reducing central nervous system adverse reactions and enhancing tolerability in elderly patients.
    Its market positioning focuses on differentiated therapeutic needs, mainly serving patients intolerant to or with unsatisfactory efficacy from existing medications, thus forming misplaced competition with the original enzalutamide and domestic generics and avoiding fierce price wars.
    With the rising incidence of prostate cancer, accelerating population aging, and official inclusion in the medical insurance catalogue in China, the drug’s market accessibility and growth potential have been greatly enhanced, making it an important force for domestic innovative drugs to replace foreign products and seize the high‑end genitourinary oncology market.
    In the future, its commercialization will be promoted through the coordination of medical insurance reimbursement, hospital access, and academic promotion. Relying on its unique clinical value and status as a domestic innovative drug, it will continue to expand its share in the rapidly growing prostate cancer drug market.
    This report is a detailed and comprehensive analysis for global Deutenzalutamide Soft Capsules market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Deutenzalutamide Soft Capsules market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Deutenzalutamide Soft Capsules market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Deutenzalutamide Soft Capsules market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Deutenzalutamide Soft Capsules market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Deutenzalutamide Soft Capsules
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Deutenzalutamide Soft Capsules market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hinovapharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Deutenzalutamide Soft Capsules market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    28 Capsules Per Box
    112 Capsules Per Bottle
    Market segment by Combined medication
    Deuteroenzalutamide in combination with Androgen Synthesis Inhibitors
    Deuteroenzalutamide in combination with Hormonal Antineoplastic Drugs
    Market segment by Production Technology
    Innovator
    Generic
    Market segment by Sales Channels
    Hospital
    Retail
    Online
    Market segment by Application
    Metastatic Castration-Resistant Prostate Cancer
    Non-Metastatic Castration-Resistant Prostate Cancer
    Metastatic Hormone-Sensitive Prostate Cancer
    Others
    Major players covered
    Hinovapharma
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Deutenzalutamide Soft Capsules product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Deutenzalutamide Soft Capsules, with price, sales quantity, revenue, and global market share of Deutenzalutamide Soft Capsules from 2021 to 2026.
    Chapter 3, the Deutenzalutamide Soft Capsules competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Deutenzalutamide Soft Capsules breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Deutenzalutamide Soft Capsules market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Deutenzalutamide Soft Capsules.
    Chapter 14 and 15, to describe Deutenzalutamide Soft Capsules sales channel, distributors, customers, research findings and conclusion.

    Buy now